Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Earnings Conference Call for Q3 FY2423-01-2024
23-01-2024
Q3FY24 Quarterly & 9MFY24 Result Announced for Rossari Biotech Ltd.
Specialty Chemicals company Rossari Biotech announced Q3FY24 & 9MFY24 results: Q3FY24 Highlights Revenue: Rs 463.8 crore, a 19% YoY increase. EBITDA: Rs 63.7 crore, up 18% YoY with an EBITDA margin of 13.7%. PAT: Rs 34.4 crore, showing a substantial increase of 34% YoY. EPS (Diluted): Rs 6.2 per share. 9MFY24 Highlights Revenue: Rs 1,357.8 crore, representing a 9% increase compared to the previous year. EBITDA: Rs 185.0 crore, achieved a 10% growth with an EBITDA margin standing at 13.6%. PAT: Rs 96.6 crore, marking a significant 23% growth compared to the same period last year. EPS (Diluted): Rs 17.5 per share. Commenting on the performance, in a joint statement, Edward Menezes, Promoter & Executive Chairman, and Sunil Chari, Promoter & Managing Director, said, "We are pleased to report yet another strong quarter, with revenues and profits showing a significant YoY increase of 19% and 34%, respectively. This performance is primarily attributed to the healthy growth witnessed in our Home, Personal Care & Performance Chemicals (HPPC) division. The division achieved a robust improvement of 31%, underpinning the efforts put in by our team to drive growth in a challenging operating environment. Despite a subdued performance from the Textile Specialty Chemicals (TSC) due to the industry headwinds and Animal Health and Nutrition (AHN) due to seasonal softness, we are optimistic about recovery in these divisions in the coming quarters. This quarter, while revenues were marginally lower QoQ, we were able to surpass our last quarter's PAT, setting a new record. On a nine-month basis also, our revenues have grown by 9% while PAT growth has been at a high of 23% Vs previous year. Our growth strategy remains focused on expanding across all business divisions. Having historically seeded new verticals within our core chemistries, our aim in the coming years is to significantly scale up these ventures. We are particularly focused on areas like specialty surfactants, phenoxy series, institutional cleaning, performance chemicals, etc. Our plan remains to tap into global markets with our existing and new products, spread into newer geographies, and increase our wallet share with existing partners. The emphasis on R&D; remains a pivotal aspect of the Company's growth and innovation strategy. Rossari's position as a premier solutions provider is fortified by its R&D; capabilities, which enable us to meet evolving market needs and solidify our role as a sought-after partner for bespoke solutions in the specialty chemicals sector. We are dedicated to leveraging our R&D; expertise to drive future growth, create value, and strengthen our reputation as a leading provider of intelligent and sustainable solutions across various industries. In the face of global challenges in the chemical industry, India is set to emerge as a major hub for chemical manufacturing. With our robust R&D; framework, strong financial foundation, expanding manufacturing capacities, and diverse product portfolio, we see significant growth opportunities in both domestic and international markets for all our business verticals. Over the next few years, we are confident that this strategic positioning will lead to strong YoY growth, enabling us to create substantial value for all our stakeholders." Result PDF22-01-2024
Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Newspaper Publication
News Paper publication of extracts of Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2023.22-01-2024
Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Investor Presentation
Intimation of Q3 FY24- Earnings Presentation.21-01-2024
Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Rossari Biotech Limited has informed the exchange regarding a Press release dated January 20, 2024 titled "Rossari Biotech announces Q3 FY24 results."21-01-2024
Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Rossari Biotech Limited has informed the exchange regarding allotment of 9350 shares.20-01-2024
Rossari Biotech Ltd - 543213 - Rossari Biotech Limited Has Informed The Exchange Regarding Board Meeting Held On January 20, 2024.
The Board of Directors of the Company at their meeting held on January 20, 2024, have interalia approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2023. (Revised)20-01-2024
Rossari Biotech Ltd - 543213 - Board Meeting Outcome for Outcome Of Board Meeting Held On January 20, 2024.
Rossari Biotech Limited has informed the Exchange regarding Board meeting held on January 20, 2024. The Board of Directors have interalia approved Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2023 and other matters.20-01-2024
Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Earnings Conference Call for investors and analysts on Tuesday, January 23, 2024 at 04:00 P.M. IST Revised intimation is only due to some technical error in the link and all other information of the Earnings Conference Call shall remain unchanged.16-01-2024
Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Earnings Conference Call for investors and analysts on Tuesday, January 23, 2024 at 04:00 P.M. IST16-01-2024